Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3

Next Previous
Trial Profile

A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MGB BP 3 (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man
  • Sponsors MGB Biopharma

    • Most Recent Events

    • 14 Jun 2016 Data will be presented at the ASM Microbe 2016 meeting, according to a MGB Biopharma media release.
    • 14 Jun 2016 Results published in a MGB Biopharma media release.
    • 09 May 2016 According to a MGB Biopharma media release, data from this study was presented during a pre-Investigational New Drug (pre-IND) meeting with the Food and Drug Administration (FDA) to discuss the regulatory strategy for the development programme of MGB-BP-3 in the US.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top